Arkolith/Insider Trading/SPRO/Form 4

Hamed Kamal

Chief Medical OfficerSpero Therapeutics, Inc. (SPRO) · full profile →Form 4 · filed Sep 15, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$50K
Net Open-Market Flow
-$50K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 13, 2023Sell(S)39K$1.27$50K576K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-048440) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML